Listed by the USPTO as MAYHEW, BRADLEY SCOTT
Tech Center 1600 • Art Units: 1621
This examiner grants 0% of resolved cases
MAYHEW, BRADLEY SCOTT works in Tech Center 1600 and Art Unit 1621. The record contains 1 resolved case, with a 0.0% allowance rate, a 0.0% interview lift, and a 393-day median to allowance. This single matter provides very limited evidence for predicting future outcomes.
Recurring applicants include Idemitsu Kosan Co.,ltd., National Cheng Kung University, and Kyungpook National University Industry-Academic Cooperation Foundation. The listed firms are BakerHostetler, Dentons Durham Jones Pinegar, and ICE MILLER LLP. Practitioners should rely on the individual prosecution history rather than generalizing from the reported metrics.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18256036 | ORGANIC ELECTROLUMINESCENT ELEMENT AND ELECTRONIC DEVICE | Non-Final OA | IDEMITSU KOSAN CO.,LTD. |
| 18523965 | METHODS OF TREATING PANCREATIC CANCER BY USING BET INHIBITOR AND PARP INHIBITOR | Non-Final OA | NATIONAL CHENG KUNG UNIVERSITY |
| 18515486 | COMPOSITION FOR INHIBITING SKIN PIGMENTATION THROUGH AUTOPHAGY ACTIVITY CONTAINING PROCYANIDIN A2 AND QUERCETIN, AS ACTIVE INGREDIENTS | Non-Final OA | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18580583 | TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH NIRAPARIB | Non-Final OA | Janssen Pharmaceutica NV |
| 18843641 | METHODS OF REDUCING HERBICIDAL STRESS USING HUMIC AND FULVIC ACID COMPOSITION TREATMENTS | Non-Final OA | PRO FARM GROUP, INC. |
| 18841688 | COMPOSITIONS COMPRISING BUTYRIC ACID AND GLUCONIC ACID FOR THE TREATMENT OF DISORDERS AND SYNDROMES ASSOCIATED WITH INTESTINAL BARRIER DYSFUNCTIONS AND DYSBIOSIS | Non-Final OA | DIFASS INTERNATIONAL S.P.A. |
| 18718599 | USE OF AILDENAFIL OR SALT THEREOF IN PREPARATION OF MEDICINE FOR PREVENTING OR TREATING ISCHEMIC BRAIN DAMAGE | Non-Final OA | ZHENAO JINYINHUA PHARMACEUTICAL |
| 18715964 | PURINE COMPOUNDS FOR TREATING DISORDERS | Non-Final OA | MARVEL BIOTECHNOLOGY |
| 18552878 | COMBINED USE OF MULTIKINASE INHIBITOR | Final Rejection | TRANSTHERA SCIENCES (NANJING), INC. |
| 18293253 | INDOLE BIPYRIMIDINE COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. |
| 18685000 | METHODS FOR TREATING AUTISM SPECTRUM DISORDERS | Non-Final OA | UNIVERSITÉ DE TOURS |
| 18516315 | SOLID DOSAGE FORMS OF A PLASMA KALLIKREIN INHIBITOR | Non-Final OA | Rezolute, Inc. |
| 18510915 | DEPOT COMPOSITIONS FOR VESICULAR MONOAMINE TRANSPORTER 2 (VMAT2) INHBITORS | Final Rejection | Foresee Pharmaceuticals Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy0.0% of resolved applications examined by Bradley Scott Mayhew were allowed (1 resolved cases), compared with 46.0% across Art Unit 1621 over the last five years.
This examiner's interview lift is +0.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Bradley Scott Mayhew took 393 days on average from filing to allowance.
Bradley Scott Mayhew examines applications in Art Unit 1621 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
